<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470599</url>
  </required_header>
  <id_info>
    <org_study_id>A3921086</org_study_id>
    <secondary_id>2011-003622-27</secondary_id>
    <nct_id>NCT01470599</nct_id>
  </id_info>
  <brief_title>A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease</brief_title>
  <official_title>A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is to establish the safety and tolerability of long-term open-label (OL)
      CP-690,550 therapy in subjects with Crohn's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjudicated Potential Cardiovascular Events</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Pre-specified cardiovascular events were adjudicated by committees of external experts who were blinded to treatment assignment. Potential events of interest (pEoI) were identified by the investigator, sponsor, review of alerts from central electrocardiogram assessments, and by search of adverse events (AE)/serious adverse event (SAE) listings for events coded to death (coronary and non-coronary), myocardial infarction (non-fatal), all coronary revascularization, unstable angina, stroke (fatal and non-fatal), transient ischemic attack, congestive heart failure, peripheral arterial vascular disease, dyspnoea, and chest pain. The independent reviewers (IRs) determined if the pEoI met the criteria for EoI classification according to the definitions summarized from the Clinical Data Interchange Standards Consortium 'Standardized Definitions for End Point Events in Cardiovascular Trials' published October 2010.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjudicated Malignancy Events</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Pre-specified malignancy events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by the investigator, sponsor, potential primary event notifications (i.e. malignancies excluding non-melanoma skin cancers) for a specific protocol, events submitted for histopathology review for potential malignancies which met the criteria for potential malignancies, and by search of AE/SAE listings for events coded to Malignant tumors Standard Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQ) (20000194). IRs determined if the pEoI met the criteria for EoI classification according to the International Classification of Diseases for Oncology, a ten-digit multi-axial classification of the site (4 characters), morphology (4 digits), behavior (1 digit), and grading (1 digit) of neoplasms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjudicated Hepatic Injury Events</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Pre-specified liver injury events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor &amp; search of clinical, safety &amp; laboratory databases (potential Hy's law event, ALT/AST ≥5 x ULN, events meeting hepatic discontinuation criteria, SAEs coded to MedDRA hepatobiliary system organ class (SOC), AEs/SAEs coded to MedDRA liver infections or infectious biliary disorders SMQ, AEs coded to MedDRA drug-induced liver injury (DILI) preferred term or any death with ALT or AST ≥3xULN, bilirubin ≥2xULN or jaundice). IRs determined if the pEoI met the criteria for EoI classification by assessing DILI (definite, highly likely, probable, possible, unlikely, unrelated or undetermined), pattern (hepatocellular, mixed, cholestatic or undetermined), likely, competing or alternative cause(s), severity (mild, moderate, severe, fatal/transplantation or undetermined), Hy's law case, recovery &amp; liver failure (all yes, no or undetermined).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjudicated Opportunistic Infection Events</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Pre-specified opportunistic infection events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor &amp; search of SAE listings for serious infections coded to MedDRA infections &amp; infestations SOC &amp;/or events meeting pre-specified criteria for IR pre-screening to determine if adjudication is required. IRs determined if the pEoI met the criteria for EoI classification according to definitions for opportunistic infections (invasive fungal infections per the European Organization for Research &amp; Treatment of Cancer/Invasive Fungal Infections Cooperative Group &amp; the National Institute of Allergy &amp; Infectious Diseases Mycoses Study Group [EORTC/MSG] Consensus Group definitions, endemic fungal infections per the EORTC/MSG Consensus Group definitions, other fungal infections, viral, bacterial &amp; parasitic infections &amp; vaccine dissemination) &amp; special interest infections (actinomycosis, Legionella &amp; mononucleosis-like toxoplasmosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjudicated Gastrointestinal (GI) Perforation Events</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Pre-specified GI perforation events were adjudicated by committees of external experts who were blinded to treatment assignment. The pEoI were identified via search of AE/SAE listings using the MedDRA GI Perforation SMQ. The IRs determined if the pEoI met the criteria for EoI classification based on whether a GI perforation occurred and if yes, the location within the GI tract, possible contributing medical conditions and/or concomitant medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjudicated Interstitial Lung Disease (ILD) Events</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Pre-specified ILD events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by searches of the clinical, safety &amp; laboratory databases (AEs coded to the MedDRA ILD SMQ and events nominated by the study clinician or clinical lead). The IRs determined if the pEoI met the criteria for EoI classification by assessment of the ILD event (probably ILD, possible ILD, alternative diagnosis likely, other or insufficient information to classify).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Remission and Sustained Clinical Remission at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of less than (&lt;) 150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. 95 percent (%) Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Remission at Baseline of This Study</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
    <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of &lt;150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Response (CDAI-100 Response) or Clinical Remission at Baseline of This Study</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
    <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of &lt;150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. Clinical response was defined as a CDAI score reduction of at least 100 points from the A3921083 study baseline value. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Relapse Among Participants in Clinical Remission at Baseline</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Relapse was defined as an increase in CDAI of more than (&gt;) 100 points from the baseline and an absolute CDAI score of &gt;220 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Data presented are rates estimated from Kaplan-Meier curves.
n = number of participants remaining at risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed CDAI Score by Week</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
    <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants remaining at risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Observed CDAI Score by Week</measure>
    <time_frame>Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
    <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline</measure>
    <time_frame>Week 48</time_frame>
    <description>Steroid-free clinical remission at Week 48 was a CDAI &lt;150 points in participants who were steroid-free at Week 48. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid Use Over Time</measure>
    <time_frame>Weeks 8, 16, 24, 36 and 48</time_frame>
    <description>Use of corticosteroids (yes or no) was recorded at baseline and throughout the study. Percentage of participants taking corticosteriod at each visit was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Switching From 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID After Initial Assignment by Visit</measure>
    <time_frame>From baseline to Week 48</time_frame>
    <description>There was a single study treatment dose adjustment allowed, at the discretion of the Investigator, from 5 mg BID to 10 mg BID or from 10 mg BID to 5 mg BID, after the initial 8 weeks of fixed open label treatment and for the remaining treatment period of 40 weeks. Percentage of participants whose study treatment were switched from 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID after initial assignment was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Change From Baseline in Fecal Calprotectin by Week</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
    <description>Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Change From Baseline in High Sensitivity C-reactive Protein (CRP) by Week</measure>
    <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 48/ET Visit</measure>
    <time_frame>Baseline and Week 48/early termination (ET)</time_frame>
    <description>The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QoL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 48/ET Visit</measure>
    <time_frame>Baseline and Week 48/ET</time_frame>
    <description>The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit</measure>
    <time_frame>Week 48/ET</time_frame>
    <description>The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. A score ≥170 corresponds to clinical remission. 95% Clopper-Pearson exact confidence interval reported for the proportions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Response to the Patient-Reported Treatment Impact (PRTI) Assessment at Week 48/ET Visit by Category</measure>
    <time_frame>Week 48/ET visit</time_frame>
    <description>The IBD PRTI modified questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to reuse the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 48/ET Visit</measure>
    <time_frame>Baseline and Week 48/ET visit</time_frame>
    <description>The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline SF-36 Component and Domain Scores at Week 48/ET Visit</measure>
    <time_frame>Baseline and Week 48/ET visit</time_frame>
    <description>The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 48/ET Visit</measure>
    <time_frame>Baseline and Week 48/ET visit</time_frame>
    <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline EQ-5D Utility Scores at Week 48/ET Visit</measure>
    <time_frame>Baseline and Week 48/ET visit</time_frame>
    <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit</measure>
    <time_frame>Baseline and Week 48/ET visit</time_frame>
    <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. n = number of participants with non-missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit</measure>
    <time_frame>Baseline and Week 48/ET visit</time_frame>
    <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Hospitalized Due to Crohn's Disease</measure>
    <time_frame>From baseline to Week 52/follow-up</time_frame>
    <description>The number of participants hospitalized due to Crohn's disease were recorded at every study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalizations Due to Crohn's Disease</measure>
    <time_frame>From baseline to Week 52/follow-up</time_frame>
    <description>The length of hospitalizations due to Crohn's disease were recorded at every study visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>5mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>ORAL TABLET, TWICE DAILY</description>
    <arm_group_label>5mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>ORAL TABLETS, TWICE DAILY</description>
    <arm_group_label>10mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who complete 26-week maintenance treatment of the A3921084 study or subjects
             who withdraw early due to A3921084 study treatment failure (see Appendix 5).

          -  Women of childbearing potential must test negative for pregnancy prior to study
             enrolment.

          -  Sexually active females of childbearing potential are required to use adequate
             contraceptive methods during the study period and until completion of the follow-up
             procedures. No specific contraceptive measures are required in male subjects during
             study participation.

        Exclusion Criteria:

          -  Subjects who have been discontinued due to protocol violation(s) (as determined by the
             Sponsor) in the A3921084 study.

          -  Subjects who were discontinued from the A3921084 study due to an adverse event.

          -  Subjects likely to require any non-elective surgery or surgery requiring overnight
             stay (with the exception of minor same day outpatient procedures that will not
             interfere with study drug dosing).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alliance Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Of The Rockies</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of Clearwater</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Endoscopy Center</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Endoscopy Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Hospital at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Service</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Medical Plaza and Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulfshore Endoscopy Center (Endoscopies Only)</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida Gastroenterology Research, LLC</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Specialists</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Central Georgia, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Ann Arbor Health and Geriatrics Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-2701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical Centers of Michigan</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Long Island Clinical Research Associates</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Nassau Gastroenterology Associates</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Endoscopy Center of Lake County</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology</name>
      <address>
        <city>Willoughby</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christus Trinity Mother Frances Endoscopy Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Health Specialists of Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopy Center of Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah HSC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wisconsin Center for Advanced Research - GI Associates, LLC</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Associates</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Public Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien Universitaetsklinik fuer Innere Medizin III</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4-MBAL, Parvo vatreshno otdelenie</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL Sofiamed OOD, Otdelenie po gastroenterologia</name>
      <address>
        <city>Sofia</city>
        <zip>1797</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. David C Pearson</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Drs. Ranjith Andrew Singh, Jamie D. Papp</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PerCuro Clinical Research Limited</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital-Mcgill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RDG centrum s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50012</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medial Pharma spol.s.r.o.</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Huriez - CHRU de Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;,1st Gastroenterology Department</name>
      <address>
        <city>Kolonaki Athens</city>
        <zip>106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterfy Sandor Utcai Korhaz, Rendelointezet es Baleseti Kozpont, I. sz. Belgyogyaszat</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pannonia Magánorvosi Centrum Kft</name>
      <address>
        <city>Budapest</city>
        <zip>1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak</name>
      <address>
        <city>Budapest</city>
        <zip>H-1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Korhaz Egeszsegugyi Szolgaltato Kozhasznu Nonprofit Kft.,</name>
      <address>
        <city>Gyongyos</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinfan Kft.</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of medicine Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Gastroenterology &amp; Hepatology, Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sendai Medical Center</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Sakura Medical Center</name>
      <address>
        <city>Chiba</city>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Soeul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parklands Medical Centre</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda Servicio Digestivo - Planta 2</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Odesa Regional Clinical Hospital&quot;. Odesa Regional Centre of Gastroenterology.</name>
      <address>
        <city>Odesa</city>
        <zip>65117</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Clinical Research Center of Medical Center &quot;Health Clinic&quot; LLC</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921086</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <results_first_submitted>June 20, 2017</results_first_submitted>
  <results_first_submitted_qc>September 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2017</results_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in participants who completed the 26-week maintenance treatment of Study A3921084 or who withdrew early due to A3921084 study treatment failure according to prespecified criteria.</recruitment_details>
      <pre_assignment_details>Participants were assigned to either the 5 milligram (mg) twice daily (BID) or 10 mg BID treatment group according to clinical remission status as assessed by Crohn’s Disease Activity Index (CDAI) score at the end of the A3921084 study treatment visit or early termination visit due to A3921084 study treatment failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tofacitinib 5 mg BID</title>
          <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tofacitinib 10 mg BID</title>
          <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient clinical response</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event not related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set (SAS) consisted of all participants enrolled in this open label (OL) extension study who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Tofacitinib 5 mg BID</title>
          <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Tofacitinib 10 mg BID</title>
          <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="12.6"/>
                    <measurement group_id="B2" value="38.2" spread="11.6"/>
                    <measurement group_id="B3" value="39.4" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjudicated Potential Cardiovascular Events</title>
        <description>Pre-specified cardiovascular events were adjudicated by committees of external experts who were blinded to treatment assignment. Potential events of interest (pEoI) were identified by the investigator, sponsor, review of alerts from central electrocardiogram assessments, and by search of adverse events (AE)/serious adverse event (SAE) listings for events coded to death (coronary and non-coronary), myocardial infarction (non-fatal), all coronary revascularization, unstable angina, stroke (fatal and non-fatal), transient ischemic attack, congestive heart failure, peripheral arterial vascular disease, dyspnoea, and chest pain. The independent reviewers (IRs) determined if the pEoI met the criteria for EoI classification according to the definitions summarized from the Clinical Data Interchange Standards Consortium ‘Standardized Definitions for End Point Events in Cardiovascular Trials’ published October 2010.</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Potential Cardiovascular Events</title>
          <description>Pre-specified cardiovascular events were adjudicated by committees of external experts who were blinded to treatment assignment. Potential events of interest (pEoI) were identified by the investigator, sponsor, review of alerts from central electrocardiogram assessments, and by search of adverse events (AE)/serious adverse event (SAE) listings for events coded to death (coronary and non-coronary), myocardial infarction (non-fatal), all coronary revascularization, unstable angina, stroke (fatal and non-fatal), transient ischemic attack, congestive heart failure, peripheral arterial vascular disease, dyspnoea, and chest pain. The independent reviewers (IRs) determined if the pEoI met the criteria for EoI classification according to the definitions summarized from the Clinical Data Interchange Standards Consortium ‘Standardized Definitions for End Point Events in Cardiovascular Trials’ published October 2010.</description>
          <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
          <units>Number of events meeting criteria</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjudicated Malignancy Events</title>
        <description>Pre-specified malignancy events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by the investigator, sponsor, potential primary event notifications (i.e. malignancies excluding non-melanoma skin cancers) for a specific protocol, events submitted for histopathology review for potential malignancies which met the criteria for potential malignancies, and by search of AE/SAE listings for events coded to Malignant tumors Standard Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQ) (20000194). IRs determined if the pEoI met the criteria for EoI classification according to the International Classification of Diseases for Oncology, a ten-digit multi-axial classification of the site (4 characters), morphology (4 digits), behavior (1 digit), and grading (1 digit) of neoplasms.</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Malignancy Events</title>
          <description>Pre-specified malignancy events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by the investigator, sponsor, potential primary event notifications (i.e. malignancies excluding non-melanoma skin cancers) for a specific protocol, events submitted for histopathology review for potential malignancies which met the criteria for potential malignancies, and by search of AE/SAE listings for events coded to Malignant tumors Standard Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQ) (20000194). IRs determined if the pEoI met the criteria for EoI classification according to the International Classification of Diseases for Oncology, a ten-digit multi-axial classification of the site (4 characters), morphology (4 digits), behavior (1 digit), and grading (1 digit) of neoplasms.</description>
          <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
          <units>Number of events meeting criteria</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Clinical Remission and Sustained Clinical Remission at Week 48</title>
        <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of less than (&lt;) 150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. 95 percent (%) Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
        <time_frame>Week 48</time_frame>
        <population>Full analysis set (FAS) - consisted of all participants enrolled in this OL extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Clinical Remission and Sustained Clinical Remission at Week 48</title>
          <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of less than (&lt;) 150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. 95 percent (%) Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
          <population>Full analysis set (FAS) - consisted of all participants enrolled in this OL extension study.</population>
          <units>Percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical remission (n=33, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.88" lower_limit="71.80" upper_limit="96.60"/>
                    <measurement group_id="O2" value="55.56" lower_limit="38.10" upper_limit="72.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained clinical remission (n=32, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="56.60" upper_limit="88.54"/>
                    <measurement group_id="O2" value="34.29" lower_limit="19.13" upper_limit="52.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Remission at Baseline of This Study</title>
        <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of &lt;150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
        <population>Participants in the FAS who met clinical remission criteria at baseline of this study</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Remission at Baseline of This Study</title>
          <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of &lt;150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
          <population>Participants in the FAS who met clinical remission criteria at baseline of this study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical remission: Baseline (n=61, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="39.76" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 8 (n=53, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.47" lower_limit="61.72" upper_limit="86.24"/>
                    <measurement group_id="O2" value="50.00" lower_limit="6.76" upper_limit="93.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 16 (n=52, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.62" lower_limit="71.92" upper_limit="93.12"/>
                    <measurement group_id="O2" value="75.00" lower_limit="19.41" upper_limit="99.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 24 (n=48, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.42" lower_limit="72.24" upper_limit="93.93"/>
                    <measurement group_id="O2" value="25.00" lower_limit="0.63" upper_limit="80.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 36 (n=40, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.50" lower_limit="79.61" upper_limit="98.43"/>
                    <measurement group_id="O2" value="33.33" lower_limit="0.84" upper_limit="90.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 48 (n=32, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.50" lower_limit="71.01" upper_limit="96.49"/>
                    <measurement group_id="O2" value="100.00" lower_limit="29.24" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 52/follow-up (n=37, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.86" lower_limit="47.46" upper_limit="79.79"/>
                    <measurement group_id="O2" value="33.33" lower_limit="0.84" upper_limit="90.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained clinical remission (n=31, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.42" lower_limit="58.90" upper_limit="90.41"/>
                    <measurement group_id="O2" value="33.33" lower_limit="0.84" upper_limit="90.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Response (CDAI-100 Response) or Clinical Remission at Baseline of This Study</title>
        <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of &lt;150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. Clinical response was defined as a CDAI score reduction of at least 100 points from the A3921083 study baseline value. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
        <population>Participants in the FAS who met clinical response or clinical remission criteria at baseline of this study</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Response (CDAI-100 Response) or Clinical Remission at Baseline of This Study</title>
          <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of &lt;150. Sustained clinical remission was defined as being in clinical remission (CDAI score &lt;150) at both Week 24 and Week 48. Clinical response was defined as a CDAI score reduction of at least 100 points from the A3921083 study baseline value. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.</description>
          <population>Participants in the FAS who met clinical response or clinical remission criteria at baseline of this study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical remission: Baseline (n=62, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.39" lower_limit="91.34" upper_limit="99.96"/>
                    <measurement group_id="O2" value="17.39" lower_limit="4.95" upper_limit="38.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 8 (n=54, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.93" lower_limit="62.36" upper_limit="86.51"/>
                    <measurement group_id="O2" value="35.00" lower_limit="15.39" upper_limit="59.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 16 (n=53, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.91" lower_limit="72.41" upper_limit="93.25"/>
                    <measurement group_id="O2" value="36.84" lower_limit="16.29" upper_limit="61.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 24 (n=49, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.67" lower_limit="70.34" upper_limit="92.68"/>
                    <measurement group_id="O2" value="43.75" lower_limit="19.75" upper_limit="70.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 36 (n=41, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.24" lower_limit="76.87" upper_limit="97.28"/>
                    <measurement group_id="O2" value="38.46" lower_limit="13.86" upper_limit="68.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 48 (n=33, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.88" lower_limit="71.80" upper_limit="96.60"/>
                    <measurement group_id="O2" value="50.00" lower_limit="18.71" upper_limit="81.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical remission: Week 52/follow-up (n=38, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.79" lower_limit="48.65" upper_limit="80.37"/>
                    <measurement group_id="O2" value="41.67" lower_limit="15.17" upper_limit="72.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained clinical remission (n=32, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="56.60" upper_limit="88.54"/>
                    <measurement group_id="O2" value="30.00" lower_limit="6.67" upper_limit="62.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Relapse Among Participants in Clinical Remission at Baseline</title>
        <description>Relapse was defined as an increase in CDAI of more than (&gt;) 100 points from the baseline and an absolute CDAI score of &gt;220 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Data presented are rates estimated from Kaplan-Meier curves.
n = number of participants remaining at risk.</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>Participants in the FAS who met clinical remission criteria at baseline of this study</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse Among Participants in Clinical Remission at Baseline</title>
          <description>Relapse was defined as an increase in CDAI of more than (&gt;) 100 points from the baseline and an absolute CDAI score of &gt;220 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Data presented are rates estimated from Kaplan-Meier curves.
n = number of participants remaining at risk.</description>
          <population>Participants in the FAS who met clinical remission criteria at baseline of this study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n=55, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" lower_limit="3.38" upper_limit="11.78"/>
                    <measurement group_id="O2" value="NA">No participants had a relapse event by Week 8.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=51, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.86" lower_limit="7.15" upper_limit="17.87"/>
                    <measurement group_id="O2" value="25.00" lower_limit="4.56" upper_limit="53.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=46, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.46" lower_limit="9.98" upper_limit="22.05"/>
                    <measurement group_id="O2" value="25.00" lower_limit="4.56" upper_limit="53.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=38, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.42" lower_limit="14.82" upper_limit="28.83"/>
                    <measurement group_id="O2" value="25.00" lower_limit="4.56" upper_limit="53.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=7, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.69" lower_limit="17.21" upper_limit="32.89"/>
                    <measurement group_id="O2" value="NA">No participants remained at risk of a relapse event by Week 48.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed CDAI Score by Week</title>
        <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants remaining at risk.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed CDAI Score by Week</title>
          <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants remaining at risk.</description>
          <population>FAS</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=62, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.13" spread="43.22"/>
                    <measurement group_id="O2" value="291.19" spread="95.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=54, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.39" spread="75.82"/>
                    <measurement group_id="O2" value="176.96" spread="82.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=53, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.58" spread="65.23"/>
                    <measurement group_id="O2" value="178.94" spread="72.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=49, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.12" spread="56.67"/>
                    <measurement group_id="O2" value="163.66" spread="79.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=41, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.34" spread="59.52"/>
                    <measurement group_id="O2" value="158.67" spread="89.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=33, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.91" spread="70.23"/>
                    <measurement group_id="O2" value="154.11" spread="71.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/Follow-up (n=38, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.32" spread="114.82"/>
                    <measurement group_id="O2" value="180.65" spread="98.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Observed CDAI Score by Week</title>
        <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants with non-missing data.</description>
        <time_frame>Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Observed CDAI Score by Week</title>
          <description>CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants with non-missing data.</description>
          <population>FAS</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n=54, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.96" spread="62.68"/>
                    <measurement group_id="O2" value="-114.31" spread="112.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=53, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.72" spread="52.25"/>
                    <measurement group_id="O2" value="-112.02" spread="111.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=49, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="44.48"/>
                    <measurement group_id="O2" value="-122.69" spread="117.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=41, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.78" spread="40.35"/>
                    <measurement group_id="O2" value="-139.81" spread="126.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=33, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.79" spread="60.09"/>
                    <measurement group_id="O2" value="-121.94" spread="129.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/Follow-up (n=38, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.66" spread="109.73"/>
                    <measurement group_id="O2" value="-107.42" spread="119.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline</title>
        <description>Steroid-free clinical remission at Week 48 was a CDAI &lt;150 points in participants who were steroid-free at Week 48. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants in FAS who were on steroids at baseline of this study</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline</title>
          <description>Steroid-free clinical remission at Week 48 was a CDAI &lt;150 points in participants who were steroid-free at Week 48. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.</description>
          <population>Participants in FAS who were on steroids at baseline of this study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" lower_limit="1.26" upper_limit="98.74"/>
                    <measurement group_id="O2" value="9.09" lower_limit="0.23" upper_limit="41.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corticosteroid Use Over Time</title>
        <description>Use of corticosteroids (yes or no) was recorded at baseline and throughout the study. Percentage of participants taking corticosteriod at each visit was reported.</description>
        <time_frame>Weeks 8, 16, 24, 36 and 48</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Corticosteroid Use Over Time</title>
          <description>Use of corticosteroids (yes or no) was recorded at baseline and throughout the study. Percentage of participants taking corticosteriod at each visit was reported.</description>
          <population>SAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61"/>
                    <measurement group_id="O2" value="20.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.84"/>
                    <measurement group_id="O2" value="21.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.84"/>
                    <measurement group_id="O2" value="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.84"/>
                    <measurement group_id="O2" value="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23"/>
                    <measurement group_id="O2" value="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61"/>
                    <measurement group_id="O2" value="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Switching From 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID After Initial Assignment by Visit</title>
        <description>There was a single study treatment dose adjustment allowed, at the discretion of the Investigator, from 5 mg BID to 10 mg BID or from 10 mg BID to 5 mg BID, after the initial 8 weeks of fixed open label treatment and for the remaining treatment period of 40 weeks. Percentage of participants whose study treatment were switched from 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID after initial assignment was reported.</description>
        <time_frame>From baseline to Week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Switching From 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID After Initial Assignment by Visit</title>
          <description>There was a single study treatment dose adjustment allowed, at the discretion of the Investigator, from 5 mg BID to 10 mg BID or from 10 mg BID to 5 mg BID, after the initial 8 weeks of fixed open label treatment and for the remaining treatment period of 40 weeks. Percentage of participants whose study treatment were switched from 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID after initial assignment was reported.</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="5.78"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.81" lower_limit="15.53" upper_limit="38.50"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" lower_limit="1.79" upper_limit="15.70"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" lower_limit="0.39" upper_limit="11.71"/>
                    <measurement group_id="O2" value="2.27" lower_limit="0.28" upper_limit="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="5.78"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.03" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="5.78"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Change From Baseline in Fecal Calprotectin by Week</title>
        <description>Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Change From Baseline in Fecal Calprotectin by Week</title>
          <description>Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. n = number of participants with non-missing data.</description>
          <population>FAS</population>
          <units>mg per kilogram (mg/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n=53, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-105.51" spread="436.41"/>
                    <measurement group_id="O2" value="-102.82" spread="310.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=54, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-144.65" spread="423.20"/>
                    <measurement group_id="O2" value="-35.28" spread="718.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=49, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-120.49" spread="511.49"/>
                    <measurement group_id="O2" value="-130.68" spread="337.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=41, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-169.92" spread="354.30"/>
                    <measurement group_id="O2" value="-133.82" spread="364.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=37, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-189.61" spread="462.61"/>
                    <measurement group_id="O2" value="-123.87" spread="376.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/Follow-up (n=48, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.33" spread="453.73"/>
                    <measurement group_id="O2" value="-109.23" spread="389.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Change From Baseline in High Sensitivity C-reactive Protein (CRP) by Week</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Change From Baseline in High Sensitivity C-reactive Protein (CRP) by Week</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. n = number of participants with non-missing data.</description>
          <population>FAS</population>
          <units>mg per liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n=61, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="14.78"/>
                    <measurement group_id="O2" value="-4.81" spread="26.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=58, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="14.54"/>
                    <measurement group_id="O2" value="-7.96" spread="25.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=54, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="17.59"/>
                    <measurement group_id="O2" value="-9.26" spread="30.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=46, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.42" spread="22.29"/>
                    <measurement group_id="O2" value="-12.09" spread="30.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=43, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.55" spread="17.81"/>
                    <measurement group_id="O2" value="-11.45" spread="31.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/Follow-up (n=54, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="21.57"/>
                    <measurement group_id="O2" value="-4.72" spread="31.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 48/ET Visit</title>
        <description>The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QoL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Week 48/early termination (ET)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 48/ET Visit</title>
          <description>The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QoL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL. n = number of participants with non-missing data.</description>
          <population>FAS</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IBDQ Total Score, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.23" spread="20.38"/>
                    <measurement group_id="O2" value="127.32" spread="34.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IBDQ Total Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.26" spread="29.89"/>
                    <measurement group_id="O2" value="144.42" spread="42.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Function Score, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.56" spread="6.86"/>
                    <measurement group_id="O2" value="40.71" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Function Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.70" spread="9.82"/>
                    <measurement group_id="O2" value="46.70" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Status Score, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.68" spread="8.58"/>
                    <measurement group_id="O2" value="48.61" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Status Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.98" spread="12.27"/>
                    <measurement group_id="O2" value="53.19" spread="17.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Symptoms Score, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.95" spread="5.36"/>
                    <measurement group_id="O2" value="17.20" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Symptoms Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.82" spread="6.28"/>
                    <measurement group_id="O2" value="20.35" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function Score, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.03" spread="3.59"/>
                    <measurement group_id="O2" value="20.80" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.75" spread="5.17"/>
                    <measurement group_id="O2" value="24.18" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 48/ET Visit</title>
        <description>The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL.</description>
        <time_frame>Baseline and Week 48/ET</time_frame>
        <population>Participants in the FAS who had non-missing data at Week 48/ET visit</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 48/ET Visit</title>
          <description>The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL.</description>
          <population>Participants in the FAS who had non-missing data at Week 48/ET visit</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IBDQ Total Score, Week 48/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.98" spread="24.93"/>
                    <measurement group_id="O2" value="18.84" spread="40.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Function Score, Week 48/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="8.30"/>
                    <measurement group_id="O2" value="6.37" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Status Score, Week 48/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.07" spread="10.48"/>
                    <measurement group_id="O2" value="5.36" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Symptoms Score, Week 48/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="4.83"/>
                    <measurement group_id="O2" value="3.45" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function Score, Week 48/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="4.24"/>
                    <measurement group_id="O2" value="3.66" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit</title>
        <description>The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. A score ≥170 corresponds to clinical remission. 95% Clopper-Pearson exact confidence interval reported for the proportions.</description>
        <time_frame>Week 48/ET</time_frame>
        <population>Participants in the FAS who had non-missing data at Week 48/ET visit</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit</title>
          <description>The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. A score ≥170 corresponds to clinical remission. 95% Clopper-Pearson exact confidence interval reported for the proportions.</description>
          <population>Participants in the FAS who had non-missing data at Week 48/ET visit</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.18" lower_limit="56.60" upper_limit="81.57"/>
                    <measurement group_id="O2" value="31.33" lower_limit="21.59" upper_limit="42.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Response to the Patient-Reported Treatment Impact (PRTI) Assessment at Week 48/ET Visit by Category</title>
        <description>The IBD PRTI modified questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to reuse the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.</description>
        <time_frame>Week 48/ET visit</time_frame>
        <population>Participants in the FAS who had a response to PRTI assessment at Week 48/ET visit</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Response to the Patient-Reported Treatment Impact (PRTI) Assessment at Week 48/ET Visit by Category</title>
          <description>The IBD PRTI modified questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to reuse the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.</description>
          <population>Participants in the FAS who had a response to PRTI assessment at Week 48/ET visit</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSA: Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA: Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA: Neither satisfied nor dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA: Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA: Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPTA: Injectable prescription medicines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPTA: Prescription medicines taken by mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPTA: Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPTA: Prescription medicines &amp; surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPTA: No treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPA: Definitely prefer the drug I am receiving now</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPA: Slight preference for drug I'm receiving now</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPA: I have no preference either way</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPA: Slight preference for previous treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPA: No, I definitely prefer my previous treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PWA: Would definitely want to use same drug again</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PWA: Might want to use the same drug again</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PWA: I am not sure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PWA: Might not want to use same drug again</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PWA: Definitely not want to use same drug again</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 48/ET Visit</title>
        <description>The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Week 48/ET visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 48/ET Visit</title>
          <description>The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.</description>
          <population>FAS</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical component score, Baseline (n=62, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.15" spread="6.73"/>
                    <measurement group_id="O2" value="37.80" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.43" spread="8.22"/>
                    <measurement group_id="O2" value="41.87" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score, Baseline (n=62, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.25" spread="9.11"/>
                    <measurement group_id="O2" value="37.17" spread="11.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.79" spread="10.64"/>
                    <measurement group_id="O2" value="39.60" spread="12.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning Domain, Baseline (n=62, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.35" spread="5.50"/>
                    <measurement group_id="O2" value="43.50" spread="10.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.40" spread="8.59"/>
                    <measurement group_id="O2" value="46.81" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical Domain, Baseline (n=62, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.97" spread="8.22"/>
                    <measurement group_id="O2" value="35.93" spread="11.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.38" spread="8.78"/>
                    <measurement group_id="O2" value="40.04" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain Domain, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.32" spread="8.55"/>
                    <measurement group_id="O2" value="35.31" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.57" spread="10.30"/>
                    <measurement group_id="O2" value="41.04" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Domain, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.60" spread="9.51"/>
                    <measurement group_id="O2" value="31.74" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.39" spread="10.08"/>
                    <measurement group_id="O2" value="33.45" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Domain, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.78" spread="10.68"/>
                    <measurement group_id="O2" value="36.92" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.06" spread="11.38"/>
                    <measurement group_id="O2" value="41.03" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning Domain, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.81" spread="7.21"/>
                    <measurement group_id="O2" value="36.38" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.42" spread="9.64"/>
                    <measurement group_id="O2" value="39.82" spread="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional Domain, Baseline (n=62, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.12" spread="8.85"/>
                    <measurement group_id="O2" value="38.55" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.97" spread="10.78"/>
                    <measurement group_id="O2" value="41.13" spread="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Domain, Baseline (n=62, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.89" spread="9.84"/>
                    <measurement group_id="O2" value="37.61" spread="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.24" spread="10.27"/>
                    <measurement group_id="O2" value="40.13" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline SF-36 Component and Domain Scores at Week 48/ET Visit</title>
        <description>The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Week 48/ET visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline SF-36 Component and Domain Scores at Week 48/ET Visit</title>
          <description>The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.</description>
          <population>FAS</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical component score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="7.17"/>
                    <measurement group_id="O2" value="4.47" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="9.05"/>
                    <measurement group_id="O2" value="3.07" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="7.50"/>
                    <measurement group_id="O2" value="3.49" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="7.87"/>
                    <measurement group_id="O2" value="4.60" spread="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="7.90"/>
                    <measurement group_id="O2" value="6.15" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="10.00"/>
                    <measurement group_id="O2" value="2.25" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="10.39"/>
                    <measurement group_id="O2" value="4.47" spread="12.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="9.09"/>
                    <measurement group_id="O2" value="3.69" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional Domain, Week 48/ET (n=57, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="10.29"/>
                    <measurement group_id="O2" value="3.28" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Domain, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="8.63"/>
                    <measurement group_id="O2" value="2.87" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 48/ET Visit</title>
        <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Week 48/ET visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 48/ET Visit</title>
          <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state. n = number of participants with non-missing data.</description>
          <population>FAS</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Utility Score, Baseline (n=62, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.21"/>
                    <measurement group_id="O2" value="0.57" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Utility Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.16"/>
                    <measurement group_id="O2" value="0.66" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline EQ-5D Utility Scores at Week 48/ET Visit</title>
        <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state.</description>
        <time_frame>Baseline and Week 48/ET visit</time_frame>
        <population>Participants in the FAS who had non-missing data at Week 48/ET visit</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline EQ-5D Utility Scores at Week 48/ET Visit</title>
          <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state.</description>
          <population>Participants in the FAS who had non-missing data at Week 48/ET visit</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.21"/>
                    <measurement group_id="O2" value="0.10" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit</title>
        <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. n = number of participants with non-missing data.</description>
        <time_frame>Baseline and Week 48/ET visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit</title>
          <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. n = number of participants with non-missing data.</description>
          <population>FAS</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS Score, Baseline (n=62, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.98" spread="16.18"/>
                    <measurement group_id="O2" value="48.60" spread="19.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Score, Week 48/ET (n=57, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.40" spread="18.54"/>
                    <measurement group_id="O2" value="57.60" spread="24.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit</title>
        <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
        <time_frame>Baseline and Week 48/ET visit</time_frame>
        <population>Participants in the FAS who had non-missing data at Week 48/ET visit</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit</title>
          <description>EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
          <population>Participants in the FAS who had non-missing data at Week 48/ET visit</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.79" spread="20.56"/>
                    <measurement group_id="O2" value="10.16" spread="26.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Hospitalized Due to Crohn’s Disease</title>
        <description>The number of participants hospitalized due to Crohn's disease were recorded at every study visit.</description>
        <time_frame>From baseline to Week 52/follow-up</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Hospitalized Due to Crohn’s Disease</title>
          <description>The number of participants hospitalized due to Crohn's disease were recorded at every study visit.</description>
          <population>SAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjudicated Hepatic Injury Events</title>
        <description>Pre-specified liver injury events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor &amp; search of clinical, safety &amp; laboratory databases (potential Hy's law event, ALT/AST ≥5 x ULN, events meeting hepatic discontinuation criteria, SAEs coded to MedDRA hepatobiliary system organ class (SOC), AEs/SAEs coded to MedDRA liver infections or infectious biliary disorders SMQ, AEs coded to MedDRA drug-induced liver injury (DILI) preferred term or any death with ALT or AST ≥3xULN, bilirubin ≥2xULN or jaundice). IRs determined if the pEoI met the criteria for EoI classification by assessing DILI (definite, highly likely, probable, possible, unlikely, unrelated or undetermined), pattern (hepatocellular, mixed, cholestatic or undetermined), likely, competing or alternative cause(s), severity (mild, moderate, severe, fatal/transplantation or undetermined), Hy’s law case, recovery &amp; liver failure (all yes, no or undetermined).</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Hepatic Injury Events</title>
          <description>Pre-specified liver injury events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor &amp; search of clinical, safety &amp; laboratory databases (potential Hy's law event, ALT/AST ≥5 x ULN, events meeting hepatic discontinuation criteria, SAEs coded to MedDRA hepatobiliary system organ class (SOC), AEs/SAEs coded to MedDRA liver infections or infectious biliary disorders SMQ, AEs coded to MedDRA drug-induced liver injury (DILI) preferred term or any death with ALT or AST ≥3xULN, bilirubin ≥2xULN or jaundice). IRs determined if the pEoI met the criteria for EoI classification by assessing DILI (definite, highly likely, probable, possible, unlikely, unrelated or undetermined), pattern (hepatocellular, mixed, cholestatic or undetermined), likely, competing or alternative cause(s), severity (mild, moderate, severe, fatal/transplantation or undetermined), Hy’s law case, recovery &amp; liver failure (all yes, no or undetermined).</description>
          <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
          <units>Number of events meeting criteria</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjudicated Opportunistic Infection Events</title>
        <description>Pre-specified opportunistic infection events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor &amp; search of SAE listings for serious infections coded to MedDRA infections &amp; infestations SOC &amp;/or events meeting pre-specified criteria for IR pre-screening to determine if adjudication is required. IRs determined if the pEoI met the criteria for EoI classification according to definitions for opportunistic infections (invasive fungal infections per the European Organization for Research &amp; Treatment of Cancer/Invasive Fungal Infections Cooperative Group &amp; the National Institute of Allergy &amp; Infectious Diseases Mycoses Study Group [EORTC/MSG] Consensus Group definitions, endemic fungal infections per the EORTC/MSG Consensus Group definitions, other fungal infections, viral, bacterial &amp; parasitic infections &amp; vaccine dissemination) &amp; special interest infections (actinomycosis, Legionella &amp; mononucleosis-like toxoplasmosis).</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Opportunistic Infection Events</title>
          <description>Pre-specified opportunistic infection events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor &amp; search of SAE listings for serious infections coded to MedDRA infections &amp; infestations SOC &amp;/or events meeting pre-specified criteria for IR pre-screening to determine if adjudication is required. IRs determined if the pEoI met the criteria for EoI classification according to definitions for opportunistic infections (invasive fungal infections per the European Organization for Research &amp; Treatment of Cancer/Invasive Fungal Infections Cooperative Group &amp; the National Institute of Allergy &amp; Infectious Diseases Mycoses Study Group [EORTC/MSG] Consensus Group definitions, endemic fungal infections per the EORTC/MSG Consensus Group definitions, other fungal infections, viral, bacterial &amp; parasitic infections &amp; vaccine dissemination) &amp; special interest infections (actinomycosis, Legionella &amp; mononucleosis-like toxoplasmosis).</description>
          <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
          <units>Number of events meeting criteria</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjudicated Gastrointestinal (GI) Perforation Events</title>
        <description>Pre-specified GI perforation events were adjudicated by committees of external experts who were blinded to treatment assignment. The pEoI were identified via search of AE/SAE listings using the MedDRA GI Perforation SMQ. The IRs determined if the pEoI met the criteria for EoI classification based on whether a GI perforation occurred and if yes, the location within the GI tract, possible contributing medical conditions and/or concomitant medications.</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Gastrointestinal (GI) Perforation Events</title>
          <description>Pre-specified GI perforation events were adjudicated by committees of external experts who were blinded to treatment assignment. The pEoI were identified via search of AE/SAE listings using the MedDRA GI Perforation SMQ. The IRs determined if the pEoI met the criteria for EoI classification based on whether a GI perforation occurred and if yes, the location within the GI tract, possible contributing medical conditions and/or concomitant medications.</description>
          <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
          <units>Number of events meeting criteria</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjudicated Interstitial Lung Disease (ILD) Events</title>
        <description>Pre-specified ILD events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by searches of the clinical, safety &amp; laboratory databases (AEs coded to the MedDRA ILD SMQ and events nominated by the study clinician or clinical lead). The IRs determined if the pEoI met the criteria for EoI classification by assessment of the ILD event (probably ILD, possible ILD, alternative diagnosis likely, other or insufficient information to classify).</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Interstitial Lung Disease (ILD) Events</title>
          <description>Pre-specified ILD events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by searches of the clinical, safety &amp; laboratory databases (AEs coded to the MedDRA ILD SMQ and events nominated by the study clinician or clinical lead). The IRs determined if the pEoI met the criteria for EoI classification by assessment of the ILD event (probably ILD, possible ILD, alternative diagnosis likely, other or insufficient information to classify).</description>
          <population>Participants in the SAS who had pEoI and were adjudicated by IRs</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospitalizations Due to Crohn’s Disease</title>
        <description>The length of hospitalizations due to Crohn's disease were recorded at every study visit.</description>
        <time_frame>From baseline to Week 52/follow-up</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 5 mg BID</title>
            <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 10 mg BID</title>
            <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospitalizations Due to Crohn’s Disease</title>
          <description>The length of hospitalizations due to Crohn's disease were recorded at every study visit.</description>
          <population>SAS</population>
          <units>Percentage of participnats</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;3 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 to 6 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 to 10 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 10 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment. Non-SAEs were recorded from time of first dose of study treatment through last participant visit.</time_frame>
      <desc>The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tofacitinib 5 mg BID</title>
          <description>Tofacitinib 5 mg tablet for oral administration at a dose of 5 mg BID for up to 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Tofacitinib 10 mg BID</title>
          <description>Tofacitinib 10 mg tablets (2 x 5 mg tablets) for oral administration at a dose of 10 mg BID for up to 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colon dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Perineal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Erectile dusfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oligomenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Testicular swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

